J. Witherspoon
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J. Witherspoon.
Acta neuropathologica communications | 2016
J. Witherspoon; Katherine G. Meilleur
Ryanodine receptor isoform-1 (RyR1) is a major calcium channel in skeletal muscle important for excitation-contraction coupling. Mutations in the RYR1 gene yield RyR1 protein dysfunction that manifests clinically as RYR1-related congenital myopathies (RYR1-RM) and/or malignant hyperthermia susceptibility (MHS). Individuals with RYR1-RM and/or MHS exhibit varying symptoms and severity. The symptoms impair quality of life and put patients at risk for early mortality, yet the cause of varying severity is not well understood. Currently, there is no Food and Drug Administration (FDA) approved treatment for RYR1-RM. Discovery of effective treatments is therefore critical, requiring knowledge of the RyR1 pathway. The purpose of this review is to compile work published to date on the RyR1 pathway and to implicate potential regions as targets for treatment. The RyR1 pathway is comprised of protein-protein interactions, protein-ligand interactions, and post-translational modifications, creating an activation/regulatory macromolecular complex. Given the complexity of this pathway, we divided these interactions and modifications into six regulatory groups. Three of several RyR1 interacting proteins, FK506-binding protein 12 (FKBP12), triadin, and calmodulin, were identified as playing important roles across all groups and may serve as promising target sites for treatment. Also, variability in disease severity may be influenced by prolongation or hyperactivity of post-translational modifications resulting from RyR1 dysfunction.
Frontiers in Neurology | 2018
Joshua J. Todd; Muslima S. Razaqyar; J. Witherspoon; Tokunbor A. Lawal; Ami Mankodi; Irene C. Chrismer; Carolyn Allen; Mary D. Meyer; Anna Kuo; Monique S. Shelton; Kim Amburgey; Dmitriy Niyazov; Pierre Fequiere; Carsten G. Bönnemann; James J. Dowling; Katherine G. Meilleur
The ryanodine receptor 1-related congenital myopathies (RYR1-RM) comprise a spectrum of slow, rare neuromuscular diseases. Affected individuals present with a mild-to-severe symptomatology ranging from proximal muscle weakness, hypotonia and joint contractures to scoliosis, ophthalmoplegia, and respiratory involvement. Although there is currently no FDA-approved treatment for RYR1-RM, our group recently conducted the first clinical trial in this patient population (NCT02362425). This study aimed to characterize novel RYR1 variants with regard to genetic, laboratory, muscle magnetic resonance imaging (MRI), and clinical findings. Genetic and histopathology reports were obtained from participant’s medical records. Alamut Visual Software was used to determine if participant’s variants had been previously reported and to assess predicted pathogenicity. Physical exams, pulmonary function tests, T1-weighted muscle MRI scans, and blood measures were completed during the abovementioned clinical trial. Six novel variants (two de novo, three dominant, and one recessive) were identified in individuals with RYR1-RM. Consistent with established RYR1-RM histopathology, cores were observed in all biopsies, except Case 6 who exhibited fiber-type disproportion. Muscle atrophy and impaired mobility with Trendelenburg gait were the most common clinical symptoms and were identified in all cases. Muscle MRI revealed substantial inter-individual variation in fatty infiltration corroborating the heterogeneity of the disease. Two individuals with dominant RYR1 variants exhibited respiratory insufficiency: a clinical symptom more commonly associated with recessive RYR1-RM cases. This study demonstrates that a genetics-led approach is suitable for the diagnosis of suspected RYR1-RM which can be corroborated through histopathology, muscle MRI and clinical examination.
Journal of Neurology | 2018
Joshua J. Todd; Vatsala Sagar; Tokunbor A. Lawal; Carolyn Allen; Muslima S. Razaqyar; Monique S. Shelton; Irene C. Chrismer; Xuemin Zhang; Mary M. Cosgrove; Anna Kuo; R. Vasavada; M. Jain; M. Waite; Dinusha Rajapakse; J. Witherspoon; Graeme Wistow; Katherine G. Meilleur
Variants in the skeletal muscle ryanodine receptor 1 gene (RYR1) result in a spectrum of RYR1-related disorders. Presentation during infancy is typical and ranges from delayed motor milestones and proximal muscle weakness to severe respiratory impairment and ophthalmoplegia. We aimed to elucidate correlations between genotype, protein structure and clinical phenotype in this rare disease population. Genetic and clinical data from 47 affected individuals were analyzed and variants mapped to the cryo-EM RyR1 structure. Comparisons of clinical severity, motor and respiratory function and symptomatology were made according to the mode of inheritance and affected RyR1 structural domain(s). Overall, 49 RYR1 variants were identified in 47 cases (dominant/de novo, n = 35; recessive, n = 12). Three variants were previously unreported. In recessive cases, facial weakness, neonatal hypotonia, ophthalmoplegia/paresis, ptosis, and scapular winging were more frequently observed than in dominant/de novo cases (all, p < 0.05). Both dominant/de novo and recessive cases exhibited core myopathy histopathology. Clinically severe cases were typically recessive or had variants localized to the RyR1 cytosolic shell domain. Motor deficits were most apparent in the MFM-32 standing and transfers dimension, [median (IQR) 85.4 (18.8)% of maximum score] and recessive cases exhibited significantly greater overall motor function impairment compared to dominant/de novo cases [79.7 (18.8)% vs. 87.5 (17.7)% of maximum score, p = 0.03]. Variant mapping revealed patterns of clinical severity across RyR1 domains, including a structural plane of interest within the RyR1 cytosolic shell, in which 84% of variants affected the bridging solenoid. We have corroborated genotype-phenotype correlations and identified RyR1 regions that may be especially sensitive to structural modification.
Orphanet Journal of Rare Diseases | 2018
J. Witherspoon; R. Vasavada; M. Waite; Monique S. Shelton; Irene C. Chrismer; Paul G. Wakim; M. Jain; Carsten G. Bönnemann; Katherine G. Meilleur
Neuromuscular Disorders | 2017
J. Todd; J. Witherspoon; M. Razaqyar; I. Chrismer; A. Kuo; M. Shelton; C. Grunseich; Ami Mankodi; A. Kokkinis; M. Waite; R. Vasavada; B. Drinkard; M. Jain; K. Meilleur
Neuromuscular Disorders | 2017
M. Shelton; J. Witherspoon; C. Allen; S. Razaqyar; M. Cortes; I. Chrismer; K. Meilleur
Neuromuscular Disorders | 2017
J. Witherspoon; R. Vasavada; M. Waite; I. Chrismer; M. Jain; K. Meilleur
Neuromuscular Disorders | 2017
J. Witherspoon; R. Vasavada; M. Waite; I. Chrismer; M. Jain; K. Meilleur
Neuromuscular Disorders | 2016
J. Witherspoon; B. Drinkard; M. Waite; I. Arveson; M. Stockman; M. Jain; K. Meilleur
Neuromuscular Disorders | 2016
I. Arveson; J. Witherspoon; B. Drinkard; M. Waite; M. Razaqyar; F. Tounkara; J. Elliott; M. Shelton; M. Jain; Carsten G. Bönnemann; K. Meilleur